Gsk (GSK) Amortization of Deferred Charges (2015 - 2026)

Gsk (GSK) has 12 years of Amortization of Deferred Charges data on file, last reported at $355.8 million in Q3 2026.

• For the quarter ending Q3 2026, Amortization of Deferred Charges changed N/A year-over-year to $355.8 million; the trailing twelve-month figure through Sep 2026 stood at -$343.2 million (changed N/A YoY), and the FY2023 full-year result was -$315.9 million, up 67.44% from the prior year.
• Amortization of Deferred Charges was $355.8 million for Q3 2026 at Gsk, up from -$301.9 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $355.8 million in Q3 2026 to a low of -$919.6 million in Q4 2022.
• A 5-year average of -$174.7 million and a median of -$99.3 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges jumped 192.85% in 2025 and tumbled 204.28% in 2026, its largest moves.
• Gsk's Amortization of Deferred Charges stood at -$919.6 million in 2022, then soared by 47.9% to -$479.1 million in 2023, then gained by 24.72% to -$360.7 million in 2024, then increased by 4.85% to -$343.2 million in 2025, then jumped by 203.68% to $355.8 million in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $355.8 million in Q3 2026, -$301.9 million in Q2 2026, and -$53.9 million in Q1 2026.